Search
Search Results
-
A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials
ObjectiveRandomized controlled trials(RCTs) of multiple drugs for Idiopathic pulmonary fibrosis(IPF) have been reported and achieved a certain degree...
-
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
BackgroundTwo antifibrotic drugs, nintedanib and pirfenidone, are available for treatment of idiopathic pulmonary fibrosis (IPF). Although efficacy...
-
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01519-9
-
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
BackgroundThe antifibrotic drugs, nintedanib and pirfenidone, inhibit the decline in forced vital capacity in patients with idiopathic pulmonary...
-
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
BackgroundThe two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC ≥50% predicted and DLco 30–79% predicted....
-
Interstitielle Lungenerkrankungen und andere progressive pulmonale Fibrosen
A wide selection of medicinal treatment options are currently available for the treatment of patients with interstitial lung diseases (ILD), so that...
-
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
BackgroundLower body mass index (BMI) and weight loss have been associated with worse outcomes in some studies in patients with pulmonary fibrosis....
-
The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks
BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on global health and economies, resulting in millions of...
-
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of...
-
Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis
BackgroundLung fibrosis is a chronic lung disease with a high mortality rate with only two approved drugs (pirfenidone and nintedanib) to attenuate...
-
Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
BackgroundThe forced vital capacity (FVC) of healthy individuals depends on their age, sex, ethnicity and height. Systemic sclerosis-associated...
-
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
BackgroundNintedanib (Ofev ® ) and pirfenidone (Esbriet ® ) are recommended by international guidelines as treatment options for idiopathic pulmonary...
-
Fibrotic remodeling in joint diseases: induction and inhibition of fibrosis in fibroblast-like synoviocytes
BackgroundWe aimed to investigate the development of synovial fibrosis in vitro and how the fibrosis can be halted. Synovial fibrosis causes joint...
